Jennifer Doudna's diagnostic spinout raises Mammoth round as it expands to therapies
When Mammoth Biosciences launched out of CRISPR pioneer Jennifer Doudna’s lab in 2018, it did so with a bit of fanfare but not a ton of cash.
Though the Series A included prominent investors such as Apple CEO Tim Cook, it only added up to $23 million, a small fraction of what some of the first generation of CRISPR companies had already raised. They added $45 million in January of 2020, the same month that Beam Therapeutics, a CRISPR company launched around the same time, was putting the finishing touches on a $180 million IPO.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.